Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Aug 30;199(1):1-7.
doi: 10.1016/j.psychres.2012.03.009. Epub 2012 Apr 20.

Predictors of antipsychotic dose changes in the CATIE schizophrenia trial

Eric Hermes  1 , Robert Rosenheck
Affiliations
Randomized Controlled Trial

Predictors of antipsychotic dose changes in the CATIE schizophrenia trial

Eric Hermes et al. Psychiatry Res. .

Abstract

Data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) was used with the objective of evaluating factors associated with antipsychotic dose changes. CATIE was a randomized, comparative effectiveness trial for patients with schizophrenia in which a clinician prescribed a double-blind, flexible dose of one of five antipsychotic medications. The mean number of capsules prescribed monthly was evaluated to identify the period following up-titration with the least sample attrition in which dose changes were likely in response to clinical factors. Demographic, efficacy and tolerability variables were evaluated in two regression models predicting a one capsule dose decrease or increase. The mean dose increased to 2.7 capsules over the first 3 months. The post-titration plateau was identified as between 3 and 6 months. Factors associated with dose increases included the Clinical Global Impression Scale at 6 months and change in the Positive and Negative Syndrome Scale between 3 and 6 months. Decreased dosing was associated only with lower patient rated at 6 months global impression of health. Neither tolerability measures, nor body weight was significantly associated with dose changes. In conclusion, dose changes were weakly associated with measures of current or changing clinical status and not affected by measures of side effects.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Sample selection for evaluation of dose increase and dose decrease from Phase 1 of the CATIE Schizophrenia Trial
Figure 2
Figure 2
The mean (standard deviation indicated by error bars) number of antipsychotic capsules by month in Phase 1 of the CATIE Schizophrenia Trial
See this image and copyright information in PMC

References

    1. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophrenia Research. 1990;3:247–251. - PubMed
    1. Barnes TR. A rating scale for drug-induced akathisia. British Journal of Psychiatry. 1989;154:672–676. - PubMed
    1. Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychotherapy and Psychosomatics. 2008;77:69–77. - PubMed
    1. Demily C, Chouinard VA, Chouinard G. Iatrogenic psychiatric-like symptom recognition. L'Encéphale. 2010;36:417–421. - PubMed
    1. Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck RA, Davis SM, Hsiao JK, Stroup TS, Lieberman JA. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research. 2008;105:175–187. - PMC - PubMed

Publication types